Polymyalgia Rheumatica

The field of rheumatology is constantly in flux.

Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.

WASHINGTON — Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab than methotrexate, according to data presented at ACR Convergence 2024.

SAN DIEGO — Diagnosing giant cell arteritis and polymyalgia rheumatica can “fascinate” and cause “trepidation” in equal measure due to their similarities and complications, said a speaker at the 2024 Congress of Clinical Rheumatology West.

Diplopia should raise clinician suspicion for giant cell arteritis when associated with cephalic symptoms and prompt the use of corticosteroids to prevent ocular ischemic complications, according to researchers.

In this video, Sebastian E. Sattui, MD, MS, discusses the efforts needed to increase awareness of polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses complications that can arise in patients with polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses exciting research on polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.

In this video, Sebastian E. Sattui, MD, MS, discusses challenges in making a polymyalgia rheumatica diagnosis.